Latest news
December 09, 2023

- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th...

December 06, 2023

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage...

December 05, 2023

Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation...

More »

AbbVie on Twitter

Looking for more news from AbbVie? Follow us on social media.


Advanced Search
Show 5102550100 per page
Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Societal impact

Our commitment to science is a commitment to better our society. Read our 2021 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2022 Annual Report on Form 10-K. Learn more



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?